DVA DAVITA INC.
Services-Misc Health & Allied Services, NEC · NYSE · SEC CIK 927066 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.1%
TTM net income YoY-2.7%
TTM EPS YoY8.0%
Revenue 3-yr CAGR4.2%
Net income 3-yr CAGR0.1%
Margins
Gross margin—
Operating margin15.8%
Net margin6.4%
FCF margin9.8%
EBITDA margin21.1%
Returns
ROE635.3%
ROA4.8%
ROIC (approx.)18.2%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets91.1%
Debt / equity—
Current ratio1.39x
Interest coverage4.00x
Cash quality & payout
Operating cash flow / net income2.23x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.64B | $12.82B |
| SG&A expense | $1.67B | $1.54B |
| Operating income | $2.04B | $2.09B |
| Interest expense | $539.92M | $435.20M |
| Pretax income | $1.35B | $1.53B |
| Income tax | $293.11M | $279.66M |
| Net income | $746.80M | $936.34M |
| EBITDA | $2.75B | $2.81B |
| EPS (basic) | 10.06 | 11.02 |
| EPS (diluted) | 9.84 | 10.73 |
| Weighted avg. shares (diluted) | 75.89M | 87.27M |
| Balance sheet | ||
| Cash & equivalents | $676.44M | $879.83M |
| Short-term investments | $24.30M | $51.06M |
| Receivables | $2.41B | $2.15B |
| Inventory | $160.63M | $134.56M |
| Current assets | $4.06B | $3.75B |
| PP&E, net | $2.81B | $2.94B |
| Goodwill | $7.55B | $7.38B |
| Intangibles | $222.12M | $197.43M |
| Total assets | $17.48B | $17.29B |
| Current liabilities | $3.14B | $2.97B |
| Short-term debt | $109.20M | $270.87M |
| Long-term debt | $10.16B | $9.18B |
| Total debt | $10.27B | $9.45B |
| Total liabilities | $16.32B | $15.19B |
| Shareholders' equity | -$651.08M | $121.12M |
| Net debt | $9.60B | $8.57B |
| Shares outstanding | 68.55M | 80.54M |
| Cash flow statement | ||
| Operating cash flow | $1.89B | $2.02B |
| Capital expenditure | $575.86M | $555.44M |
| Free cash flow | $1.31B | $1.47B |
| Investing cash flow | -$654.95M | -$771.43M |
| Financing cash flow | -$1.37B | -$816.94M |
| Depreciation & amortization | $708.25M | $716.40M |
| Stock-based compensation | $139.95M | $102.79M |
| Dividends paid | $0 | $0 |
| Share buybacks | $1.31B | $1.39B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.